9 May 2022 in Burns & Trauma
A keloid is a disease of excessive fibrosis that is characterized by the aberrant proliferation of fibroblasts. However, the molecular mechanisms of fibroblasts during the development of keloids remain unclear. This study aims to identify new molecular targets that promote the proliferation and migration of keloid fibroblasts, providing new ideas for the prevention and treatment of keloids. We utilized bioinformatics tools to analyze data from keloid fibroblasts (KFs) available in the Gene Expression Omnibus (GEO) database to identify the key genes involved in keloid development. Homeobox C6 (HOXC6) emerged as a hub gene in KFs from the GEO database was verified in keloid tissue samples and KFs using reverse transcription-quantitative polymerase chain reaction, western blot (WB) and immunohistochemistry. Subsequently, the effects of downregulated HOXC6 expression on the cellular behaviors of KFs were examined by performing Cell Counting Kit-8, flow cytometry, transwell migration and WB assays. Meanwhile, we performed transcriptome sequencing and gene set enrichment analysis (GSEA) to further explore HOXC6-related mechanisms and validated the signaling pathways by performing a series of experiments. HOXC6 was the top-ranking hub gene of KFs in microarray datasets from GEO and was upregulated in keloid tissue samples and KFs. Downregulation of HOXC6 inhibited proliferation, migration and extracellular matrix (ECM) accumulation and promoted KF apoptosis. GSEA predicted that the hypoxia signaling pathway was associated with HOXC6 in KFs. Transcriptome sequencing suggested that the extracellular regulated protein kinase (ERK) pathway was one of the downstream pathways of HOXC6 in KFs. Our experiments confirmed that hypoxia-inducible factor-1α (HIF-1α) upregulates HOXC6, contributing to KFs proliferation, migration, apoptosis inhibition and collagen accumulation through the ERK signaling pathway. Our findings first revealed that HOXC6 acts as an oncogenic driver in the molecular mechanisms of fibroblasts in keloids. The HIF-1α/HOXC6/ERK axis promotes proliferation, migration and ECM production by KFs, contributing to the progression of keloids. Taken together, HOXC6 may serve as a promising novel therapeutic target and new focus for research designed to understand the pathogenesis of keloids.
28 January 2023 in Journal of Investigative Dermatology
1 October 2024 in Journal of Cellular and Molecular Medicine
Human papillomavirus (HPV) infection can cause condyloma acuminatum (CA), which is characterized by a high incidence and a propensity for recurrence after treatment. Angiogenesis plays an important role in the occurrence and development of CA. Seryl‐tRNA synthetase (SerRS) is a newly identified, potent anti‐angiogenic factor that directly binds to the vascular endothelial growth factor (VEGFA) promoter, thereby suppressing its transcription. Emodin is a natural anthraquinone derivative that can promote SerRS expression. This study aimed to investigate the effects of emodin on CA and explore combined treatment strategies. The HPV‐infected cell line SiHa was treated with either DMSO, emodin, ALA‐PDT or a combination of emodin and ALA‐PDT. We observed the effects on cell proliferation, apoptosis and the SerRS‐VEGFA pathway. Our findings demonstrated that emodin targets angiogenesis through the SerRS‐VEGFA pathway, resulting in the inhibition of SiHa cell proliferation and promotion of apoptosis (p < 0.001). To verify the therapeutic effect of emodin combined with ALA‐PDT on HPV‐associated tumours in vivo, we established an animal xenograft model by subcutaneously inoculating mice with SiHa cells (n = 4). The results showed that the combination of emodin and ALA‐PDT significantly inhibited the expression of VEGFA to inhibit angiogenesis (p < 0.001), thus showing an inhibitory effect on tumour (p < 0.001). Furthermore, we determined that the mechanism underlying the decrease in VEGFA expression after emodin combined with ALA‐PDT in CA may be attributed to the promotion of SerRS expression (p < 0.001). The combination of emodin and ALA‐PDT holds promise as a novel therapeutic target for CA by targeting neovascularization in condyloma tissues.
2 May 2024 in Molecular Carcinogenesis
19 February 2026 in Photodiagnosis and Photodynamic Therapy
Hemoporfin-mediated photodynamic therapy (HMME-PDT) is an established treatment for port-wine stains (PWS), but hypertrophic or nodular lesions often respond poorly, and the molecular mechanisms that govern treatment sensitivity remain unclear. The Ataxia Telangiectasia Mutated (ATM)-Seryl-tRNA synthetase (SerRS)-Vascular endothelial growth factor A (VEGFA) pathway has recently been implicated in hypoxia- and DNA damage-driven angiogenesis. Human umbilical vein endothelial cells (HUVECs) were treated with HMME-PDT and/or all-trans retinoic acid (tRA). Cell viability was assessed by CCK-8 assay, angiogenic activity by tube formation assay, and mRNA expression of ATM, SerRS and VEGFA by quantitative real-time PCR. Protein levels of ATM, phosphorylated ATM (p-ATM), SerRS and VEGFA were evaluated by Western blotting. HMME-PDT significantly inhibited HUVEC viability and tube formation in a concentration- and light dose-dependent manner. HMME-PDT decreased total ATM and, more prominently, p-ATM, while upregulating SerRS and downregulating VEGFA at both mRNA and protein levels. tRA alone dose- and time-dependently reduced HUVEC proliferation, increased SerRS expression and suppressed VEGFA expression. Combined treatment with tRA and HMME-PDT produced the greatest inhibition of tube formation and the strongest induction of SerRS together with the most pronounced reduction in VEGFA, whereas changes in ATM and p-ATM were mainly driven by HMME-PDT. HMME-PDT exerts anti-angiogenic effects at least in part by modulating the ATM-SerRS-VEGFA axis in endothelial cells. Pharmacologic upregulation of SerRS by tRA further enhances VEGFA suppression and inhibition of angiogenesis, indicating a synergistic interaction between tRA and HMME-PDT. These findings provide a mechanistic rationale for tRA-augmented HMME-PDT as a potential strategy to improve outcomes in refractory PWS.